From left:Amylyx Co-founders and Co-CEOs Justin Klee and Josh Cohen/Courtesy Amylyx
Wednesday offers a rare opportunity for Amylyx Pharmaceuticals, which will go before the FDAs Peripheral and Central Nervous System Drugs Advisory Committee in a second attempt to win recommendation for its amyotrophic lateral sclerosis (ALS) drug, AMX0035.
The FDA provided briefing documents Friday, and despite the unusual second adcomm, it does not appear to be convinced. To be approved, AMX0035 must meet substantial evidence of effectiveness, which may be derived by either a single very persuasive trial or a single adequate and well-controlled study plus confirmatory evidence, the documents state.
In March, the PCNSDAC voted 6-4 that the Phase II CENTAUR trial was not sufficient to prove efficacy in ALS. This trial, made up of 137 participants, showed a median overall survival (mOS) rate of 4.8 months compared to placebo.
Amylyx subsequently submitted additional analyses of the survival data from this trial and an open-label extension study. The agency considered this new data a major amendment and extended the drugs review time by three months. Recognizing the substantial unmet medical need in ALS, it again convened the PCNSDAC and here we are.
Wednesday's vote carries a higher burden for Amylyx to prove - that the data supporting AMX0035 is sufficient to "support approval".
The Case
Amylyx will present new analysis using the Rank Preserving Structural Failure Time Model (RPSFTM) to adjust for the effect of treatment crossover. This refers to patients who swtiched from treatment to placebo following the Phase II trial. In this analysis, the mOS in the intent-to-treat (ITT) population is 9.7 months.
The company also submitted analyses using natural history as a control to estimate survival time, as well as biomarker evidence from the Phase II PEGASUS trial of AMX0035 in Alzheimers disease (AD).
While Amylyx is presenting the above as confirmatory evidence, the FDA wrote, The presented RPSFTM analysis is not independent data and is simply a new method for analyzing the same survival data presented in the original NDA submission."
Of the biomarker analysis, the regulator said, The submitted biomarker data are not clear evidence of a CNS effect or a potential clinical benefit in patients with ALS.
AMX0035 is currently being assessed in a Phase III trial and the FDA expressed an inclination to wait until its completion, which is expected late next year or in early 2024. The PHOENIX trial will enroll approximately 600 individuals across the United States and Europe.
This places the Agency in a challenging situation of potentially making a regulatory decision that may not be subsequently aligned with the results of the ongoing study, the FDA stated.
For its part, Amylyx released the following statement Friday: AMX0035 is the first drug candidate to show benefit on function and survival in ALS in a randomized, placebo-controlled clinical trial, as a standalone therapy or when added to existing approved treatments.
Thought Leaders Weigh In
In ALS, which carries a typical death sentence of 3-5 years after diagnosis, any survival increase is enticing, particularly in a space that has seen little progress in recent years. BioSpace reached out to ALS thought leaders and drug developers prior to the adcomm for their perspectives.
Based on the data presented from their phase II trial, the Amylyx drug appears to offer a benefit in terms of slowing of disease progression and a possible survival benefit, said Stan E. Abel, CEO of ProJenX Inc., in an email.
ProJenX is in Phase I development with Prosetin, a mitogen-activated protein kinase (MAP4K) inhibitor targeting endoplasmic reticulum (ER) stress, a common feature in sporadic and familiar forms of ALS.
Given the benign safety profile, it is encouraging to see the FDA take a careful look at all the data, Abel continued. This was an area of consensus between Amylyx and the FDA in March, with both concluding AMX0035 did not pose a safety risk to patients.
There is another potential wrinkle in the case of AMX0035. In June, Amylyx notched its first regulatory approval when Health Canada approved the drug, now known as Albrioza, conditional on the results of the PHOENIX trial.
If AMX0035 does not receive approval in the U.S. or other countries, Abel noted it would add uncertainty and confusion to an already challenging clinical trial environment. He added that people living with ALS would likely seek treatment across borders which adds a significant burden to managing their care and [would put] more strain on the drug importation phenomenon.
Dr. Merit Cudkowicz, director of the Sean M. Healey & AMG Center for ALS and chief of neurology at Massachusetts General Hospital, shared her thoughts in an email.
A positive phase II study like Centaur where there is slowing of loss of function, prolongation of life - a survival benefit - and no safety issues is something we need to be able to get to our patients in the U.S., Cudkowicz said.
With recent breakthroughs in the space, there is a sense of momentum right now. If AMX0035 is ultimately approved, it will provide much needed positive news in the space and encourage further investment in other new promising therapies, Abel said.
Regulatory Flexibility for ALS
The ALS community has been calling for regulatory flexibility since the FDA approved Biogen's Aduhelmfor Alzheimers in June 2021.
Of the Sept. 7 adcomm, Stacy Lindborg, Ph.D., EVP and chief development officer at BrainStorm Cell Therapeutics said, We hope that a positiverecommendation would encourage the FDA to exercise regulatory flexibility.
BrainStorm is in the final stages of completing a BLA for NurOwn, an ALS candidate made up of autologous mesenchymal stem cells (MSCs) and neurotrophic factors (NTFs). Lindborg noted that the totality of evidence for NurOwn [brings] to light valuable insights on the nature of ALS research and biomarkers as predictors of clinical response.
In June, the FDA unveiled its Action Plan for Rare Neurodegenerative Diseases including ALS.The five-year strategy intends to improve and extend the lives of people living with rare neurodegenerative diseases by advancing the development of safe and effective medical products and facilitating patient access to novel treatments.
Cudkowicz made a comparison to the FDAs approval process for drugs in serious cancer indications.
The oncology branch of FDA approves drugs with smaller effects on survival based on a single study, and it would be a huge step forward in ALS if single studies like this could be approved conditional on future studies, she wrote in the same email.
Abel shared his thoughts on both the adcomm and the Action Plan.
The action plan for rare neurodegenerative diseases and this second Amylyx adcomm are both important steps that signal the FDAs willingness to apply thoughtful regulatory standards which take disease-specific considerations into account," he said.
Lindborg concurred, stating, FDAs release of the plan is an important step in adopting an outlook that prioritizes action to move potential therapies forward.
SVB Senior Research Analyst Marc Goodman provided a summary of his most recent note on Amylyx.
Significant unmet need in ALS with only two existing SOC (standard of care) agents that dont work very well should drive expedited regulatory approvals of AMX0035 and strong uptake, in combination with SOC agents," he wrote.
If AMX0035 does receive FDA approval, Cudkowicz said, It would strongly encourage more trials of other therapeutic approaches in ALS and would be a huge positive for the field. A negative opinion, she said, would be hugely disappointing for people living with ALS today and for ALS clinicians. It could risk putting the field back with less interest from industry.
BioSpace will have continued coverage of the Amylyx adcomm this week.
See the article here:
ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm - BioSpace
- Heres How Fasting Benefits Your Mental and Physical Wellbeing - News18 - October 4th, 2022
- Asymmetrex Gives First Cell Culture Core Facility Introduction to Online Rapid Stem Cell Counting in the Institute for Applied Life Sciences at... - September 25th, 2022
- Asymmetrex's Introduction of Online Calculators for Determination of the Dosage of Therapeutic Stem Cells Announced as a Reformation in Stem Cell... - September 16th, 2022
- UMass Dartmouth awarded $750000 Massachusetts Life Science grant to diversify the field - New Bedford Guide - September 16th, 2022
- Scientists convert kidney to universal O blood type - Freethink - August 30th, 2022
- Case Study: SARS-CoV-2 Virus Infecting the Inner Ear - Victoria News - August 14th, 2022
- Evidence Is Growing That LSD Improves Learning and Memory - Futurism - August 14th, 2022
- Rice University: Rice, Baylor developing implants to heal heart attack injuries | India Education | Latest Education News | Global Educational News |... - August 14th, 2022
- Iconic everyday inventions and the women behind them - YourStory - August 14th, 2022
- Head to Head Analysis: VolitionRx (NYSE:VNRX) vs. Intellia Therapeutics (NASDAQ:NTLA) - Defense World - August 14th, 2022
- Man who saved life as stem cell donor urges others to help his friend find a match after five-year search - Lancashire Evening Post - August 5th, 2022
- The 3D Cell Culture Market is expected to reach a value of USD 3721.86 Million by 2027, at a CAGR of 13.4% (2021 2027) - Digital Journal - August 5th, 2022
- Flow Cytometry Market is expected to reach a value of USD 11467.80 Million by 2027, at a CAGR of 8.88% over the forecast period (2021 2027) - Digital... - July 27th, 2022
- Stem Cells Market Competitive Insights And Global Outlook 2022 To 2027 Vcanbio, Boyalife, Beikebiotech, Thermo Fisher Scientific (Massachusetts, US),... - July 11th, 2022
- Seven UMass Amherst Faculty Members Receive NSF CAREER Awards in 2021-22 Academic Year - UMass News and Media Relations - July 11th, 2022
- BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal - GuruFocus.com - June 22nd, 2022
- Asymmetrex Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine... - June 13th, 2022
- Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD - OncLive - June 4th, 2022
- Stem Cells Market 2022 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 The Greater Binghamton Business Journal - The... - June 4th, 2022
- Sheldon Krimsky, Who Warned of Profit Motive in Science, Dies at 80 - The New York Times - May 15th, 2022
- We met during cancer treatments, fell in love and got married - New York Post - May 15th, 2022
- Ticking time bombs of DNA mutation may dictate when animals die - Livescience.com - May 2nd, 2022
- Sen. Orrin Hatch's legacy tracks the GOP's evolution on health - Wisconsin Public Radio - May 2nd, 2022
- Emerging interactions between skin stem cells and their ... - April 6th, 2022
- Priothera Receives R&D Innovation Loan from Bpifrance - PR Newswire - April 6th, 2022
- What is Regeneration? review: A dive into the science of regrowth - New Scientist - April 6th, 2022
- 5 FDA decisions to watch in the second quarter - BioPharma Dive - April 6th, 2022
- Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners - The New York Academy of Sciences - April 6th, 2022
- MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults... - March 25th, 2022
- January 2022: 2021 Papers of the year - Environmental Factor Newsletter - January 5th, 2022
- Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL - www.oncnursingnews.com/ - January 5th, 2022
- Stem cells: Sources, types, and uses - Medical News Today - December 24th, 2021
- cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required - OncLive - October 28th, 2021
- Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting - PRNewswire - June 23rd, 2021
- Infertility: Men account for at least half of cases. So why have women shouldered the blame? - The Irish Times - June 23rd, 2021
- On systemic sources of early life stress, and empathetic responses - MIT News - June 6th, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 1st, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium - GlobeNewswire - February 1st, 2021
- NurOwn May Be Given to Early ALS Patients in US Who Finished Phase... - ALS News Today - December 20th, 2020
- Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech - October 24th, 2020
- Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor - September 5th, 2020
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise - July 2nd, 2020
- Startup targets glioblastoma tumors with CAR-T therapy - FierceBiotech - May 28th, 2020
- Infrared Laser Treatment of TBI, PTSD, and Depression: An Expert Perspective - Psychiatry Advisor - April 3rd, 2020
- 10 Of The Biggest World Revelations In The 21st Century - World Atlas - February 29th, 2020
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace - January 10th, 2020
- Firm adds a new wrinkle to anti-aging products - Williamson Daily News - January 5th, 2020
- Top Emerging Technologies of the Year - Technowize - December 29th, 2019
- New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments - PR Web - November 9th, 2019
- Exercise found to block chronic inflammation in mice - Harvard Gazette - November 9th, 2019
- Arkuda bags $44M to target progranulin and head off inherited dementia - FierceBiotech - November 9th, 2019
- New study reveals why breast cancer spreads to the brain - USC News - October 23rd, 2019
- Comparison of Merus N.V. (MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) - MS Wkly - October 23rd, 2019
- Reviewing Cellectis S.A. (CLLS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - MS Wkly - October 23rd, 2019
- Massachusetts Stem Cells | Stem Cell TV - September 10th, 2019
- Chronic variable stress activates hematopoietic stem cells ... - April 12th, 2019
- Boston, MA, Stem Cell Transplant, Weston, Nantucket ... - January 10th, 2019
- Cloning/Embryonic Stem Cells - National Human Genome ... - July 5th, 2018
- Alternate Methods for Preparing Pluripotent Stem Cells ... - September 25th, 2017
- Doubts raised about CRISPR gene-editing study in human embryos - Nature.com - September 2nd, 2017
- For Lowell native, stem cell match becomes a match as friends - Lowell Sun - September 2nd, 2017
- Lymphoma Patient's Brain Tumor Disappeared After She Received JCAR017, Study Reports - Lymphoma News Today - September 2nd, 2017
- Asymmetrex Introduces New Contract Service For Producing ... - PR Web (press release) - August 29th, 2017
- ORGANOID - Science Magazine - August 27th, 2017
- Current humanized mice not good models for studying stem cell transplants, say researchers - Scope (blog) - August 27th, 2017
- Mouse Model of Human Immune System Inadequate for Stem Cell ... - Technology Networks - August 27th, 2017
- CRISPR fixes disease gene in viable human embryos - Nature.com - August 6th, 2017
- X4 joins hands with Yale on rare disease program - FierceBiotech - August 6th, 2017
- TGF-1: ALS Astrocytes' Secret Sauce? - ALS Research Forum - August 6th, 2017
- From Stem Cells to Human Development - September 2016 ... - December 4th, 2016
- Stem cell controversy - Wikipedia - December 1st, 2016
- What Are Stem Cells? - Massachusetts General Hospital ... - November 22nd, 2016
- New England Cord Blood Bank - Cord Blood and Cord Tissue ... - November 22nd, 2016
- Stem-cell-based therapy promising for treatment of breast ... - September 26th, 2016
- Stem Cell FAQ - Massachusetts General Hospital, Boston, MA - July 27th, 2016
- Stem Cell Facts - University of Massachusetts Medical School - July 27th, 2016
- Scientists engineer toxin-secreting stem cells to treat ... - October 19th, 2015
- Cloning/Embryonic Stem Cells - Genome.gov - October 19th, 2015
- Biomedical engineer developing nanomaterial for healing broken bones - March 18th, 2015
- Researchers identify a vital protein that can determine head and brain development - March 13th, 2015